ENO1 and melanoma: Analysis of the published data showed that the inhibition of PPARγ decreased the mRNA level of ENO1 in BLCA cells (Supplementary Fig. S14D) [33, 34], while Rosiglitazone (a PPARγ agonist) could increase the transcription level of ENO1 in melanoma cells (Supplementary Fig. S14E).